Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$71.02
+1.5%
$72.30
$67.14
▼
$87.76
$1.61B0.45390,259 shs44,112 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$36.48
$31.60
$18.80
▼
$36.67
$1.46B0.211.07 million shsN/A
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$12.75
$5.26
▼
$14.00
$437.29MN/A503,865 shsN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$23.31
-1.9%
$31.06
$22.06
▼
$52.93
$1.38B1.4469,706 shs91,151 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-1.27%-1.77%-3.18%-10.29%-14.62%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
+0.01%-0.01%+0.40%+49.77%+52.78%
Pfenex Inc. stock logo
PFNX
Pfenex
0.00%0.00%0.00%0.00%0.00%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-4.27%-8.47%-13.82%-51.58%-5.38%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$71.02
+1.5%
$72.30
$67.14
▼
$87.76
$1.61B0.45390,259 shs44,112 shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$36.48
$31.60
$18.80
▼
$36.67
$1.46B0.211.07 million shsN/A
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$12.75
$5.26
▼
$14.00
$437.29MN/A503,865 shsN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
$23.31
-1.9%
$31.06
$22.06
▼
$52.93
$1.38B1.4469,706 shs91,151 shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
-1.27%-1.77%-3.18%-10.29%-14.62%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
+0.01%-0.01%+0.40%+49.77%+52.78%
Pfenex Inc. stock logo
PFNX
Pfenex
0.00%0.00%0.00%0.00%0.00%
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-4.27%-8.47%-13.82%-51.58%-5.38%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
2.43
Hold$100.0040.80% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.09
Hold$33.33-8.63% Downside
Pfenex Inc. stock logo
PFNX
Pfenex
0.00
N/AN/AN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
2.93
Moderate Buy$64.50176.66% Upside

Current Analyst Ratings Breakdown

Latest PFNX, ANIP, RAPP, and PCRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/9/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
UpgradeHold (C-) ➝ Hold (C)
11/6/2026
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Boost Price TargetBuy$119.00 ➝ $121.00
11/5/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Lower Price TargetOverweight$50.00 ➝ $47.00
11/5/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Lower Price TargetBuy$71.00 ➝ $64.00
11/5/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Lower Price TargetBuy$70.00 ➝ $66.00
11/4/2026
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
Reiterated RatingHold (C+)
11/4/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Set Price Target$73.00
11/3/2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
UpgradeStrong Sell ➝ Hold
10/21/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Lower Price TargetOverweight$51.00 ➝ $50.00
10/21/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Boost Price TargetBuy$50.00 ➝ $82.00
10/20/2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
Reiterated RatingOutperform
(Data available from 11/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$883.37M1.83$9.95 per share7.14$28.03 per share2.53
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$726.41M2.01$3.86 per share9.46$17.77 per share2.05
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/A$6.60 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$78.34M$5.0214.158.652.2211.22%28.34%11.18%N/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$7.03M$0.3539.2315.52N/A5.08%11.91%6.61%N/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$111.48M-$3.17N/AN/AN/AN/A-34.00%-31.89%N/A

Latest PFNX, ANIP, RAPP, and PCRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026 & Acquisition
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
$2.18$2.70+$0.52$1.51$280.59 million$290.78 million
11/5/2026Q3 2026
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$0.7520$0.70-$0.0520$0.70$181.94 million$176.65 million
11/4/2026Q3 2026
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
-$1.20-$0.84+$0.36-$0.84$0.01 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
0.92
2.75
2.33
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.41
4.68
3.65
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A
20.07
20.07

Institutional Ownership

CompanyInstitutional Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
76.05%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
8.10%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
12.48%
CompanyEmployeesShares OutstandingFree FloatOptionable
ANI Pharmaceuticals, Inc. stock logo
ANIP
ANI Pharmaceuticals
97022.73 million20.89 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
82940.10 million37.53 millionOptionable
Pfenex Inc. stock logo
PFNX
Pfenex
7134.30 millionN/ANot Optionable
Rapport Therapeutics, Inc. stock logo
RAPP
Rapport Therapeutics
8459.28 million51.88 millionOptionable

Recent News About These Companies

HC Wainwright Analysts Increase Earnings Estimates for RAPP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ANI Pharmaceuticals stock logo

ANI Pharmaceuticals NASDAQ:ANIP

$71.02 +1.03 (+1.48%)
As of 11:38 AM Eastern
This is a fair market value price provided by Massive. Learn more.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$36.48 0.00 (0.00%)
As of 11/17/2026

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Pfenex stock logo

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)
As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Rapport Therapeutics stock logo

Rapport Therapeutics NASDAQ:RAPP

$23.31 -0.45 (-1.88%)
As of 11:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.